You just read:

DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

News provided by

DelMar Pharmaceuticals, Inc.

Jun 22, 2017, 08:30 ET